Beam Global Reports Record Year End 2023 Operating Results
April 16, 2024 19:02 ET
|
Beam Global
Beam Global Reports Record Year End 2023 Operating Results
James River Completes Sale of Casualty Reinsurance Business to Fleming Holdings
April 16, 2024 18:35 ET
|
James River Group Holdings, Ltd.
PEMBROKE, Bermuda, April 16, 2024 (GLOBE NEWSWIRE) -- James River Group Holdings, Ltd. (“James River” or the “Company”) (NASDAQ: JRVR) today announced that Fleming Intermediate Holdings (“Fleming”)...
Beam Global to Release 2023 Operating Results, Conference Call Scheduled for April 17, 2024 at 4:30 p.m. ET
April 16, 2024 18:34 ET
|
Beam Global
Beam Global to Release 2023 Operating Results, Conference Call Scheduled for April 17, 2024 at 4:30 p.m. ET
Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 16, 2024 18:21 ET
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, April 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the closing of its underwritten public offering of 11,916,667 shares of its common stock at...
Alvotech hlýtur markaðsleyfi í Bandaríkjunum fyrir Selarsdi (ustekinumab-aekn) líftæknilyfjahliðstæðu við Stelara
April 16, 2024 17:30 ET
|
Alvotech
Markaðsleyfið er fyrir notkun lyfsins til meðferðar bæði á fullorðnum og börnum Þetta er önnur líftæknilyfjahliðstæða Alvotech sem hlýtur markaðsleyfi í Bandaríkjunum Gert er ráð fyrir að Selarsdi...
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
April 16, 2024 17:30 ET
|
Alvotech
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be marketed in the...
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
April 16, 2024 17:30 ET
|
Alvotech
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be marketed in the...
Dorman Products, Inc. Announces Date to Report First Quarter 2024 Financial Results
April 16, 2024 17:00 ET
|
Dorman Products, Inc.
COLMAR, Pa., April 16, 2024 (GLOBE NEWSWIRE) -- Dorman Products, Inc. (the “Company” or “Dorman”) (NASDAQ: DORM) today announced the Company will report its financial results for the first quarter...
Symbotic to Stream Investor Day Webcast on May 9, 2024
April 16, 2024 17:00 ET
|
Symbotic Inc.
Symbotic to Stream Investor Day Webcast on May 9, 2024 at 3:00 PM ET. Register at: https://www.symbotic.com/investor-day-2024-webcast/
Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024
April 16, 2024 17:00 ET
|
Cingulate Inc.
KANSAS CITY, Kan., April 16, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...